Evidence map›Paper›PMID 30552135›Full record

Trial reportDiabetes care2019

Pancreas Volume Declines During the First Year After Diagnosis of Type 1 Diabetes and Exhibits Altered Diffusion at Disease Onset.

John Virostko, Jon Williams, Melissa Hilmes, Chris Bowman, Jordan J Wright, Liping Du, Hakmook Kang, William E Russell, Alvin C Powers, Daniel J Moore

Registry-linked trialAbstract readClinical Trial
In one paragraph

Trial report in Diabetes care, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03585153 (Multicenter Assessment of the Pancreas in Type 1 Diabetes), which is not on this map. Cited by 78 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03585153 enrolling by invitationnot on this map

Multicenter Assessment of the Pancreas in Type 1 Diabetes

TypeobservationalSponsorVanderbilt University Medical CenterRan2014 to 2050Enrolled250ConditionsDiabetes MellitusArmsNon-contrast magnetic resonance imaging
3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Journal of the Endocrine Society · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

John VirostkoDepartment of Diagnostic Medicine, Dell Medical School, University of Texas at Austin, Austin, TX jack.virostko@austin.utexas.edu al.powers@vanderbilt.edu daniel.moore@vanderbilt.edu.ORCID 0000-0003-3413-8801
Jon WilliamsDivision of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.
Melissa HilmesDepartment of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN.
Chris BowmanDivision of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.
Jordan J WrightDivision of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.
Liping DuDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN.
Hakmook KangDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN.
William E RussellDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, TN.
Alvin C PowersDivision of Diabetes, Endocrinology, and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN jack.virostko@austin.utexas.edu al.powers@vanderbilt.edu daniel.moore@vanderbilt.edu.ORCID 0000-0003-1941-5786
Daniel J MooreDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, TN jack.virostko@austin.utexas.edu al.powers@vanderbilt.edu daniel.moore@vanderbilt.edu.ORCID 0000-0002-6889-9345

Funding

Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7M
The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
Vanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ALVIN C POWERS · 2012 to 2026
$29.3M
UCSF Trialnet: A Phase II Trial of Imatimib in New Onset Type I DiabetesU01DK061010 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GITELMAN, STEPHEN E · 2001 to 2018
$8.1M
Research Project: Sensory and Multisensory Contributions to AutismU54HD083211 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DYKENS, ELISABETH MAY · 2015 to 2019
$7.1M
Vanderbilt University: Clinical Center Application, Type 1 Diabetes TrialNetU01DK085465 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RUSSELL, WILLIAM E · 2009 to 2018
$4.8M
Islet Imaging with Monoclonal AntibodiesR01DK094199 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI LIU, GUOZHENG, POWERS, ALVIN C · 2011 to 2015
$2.1M
Chicagoland Diabetes TrialNet Clinical CenterU01DK103153 · NIDDK · UNIVERSITY OF CHICAGO · PI PHILIPSON, LOUIS H. · 2014 to 2018
$1.4M
The Vanderbilt Institute for Clinical and Translational Research (VICTR)TL1TR000447 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$1.2M
NCATS NIH HHS TL1 TR000447NCATS NIH HHS UL1 TR000445NCATS NIH HHS UL1 TR002243NICHD NIH HHS U54 HD083211NIDDK NIH HHS P30 DK020593NIDDK NIH HHS R01 DK094199NIDDK NIH HHS U01 DK061010NIDDK NIH HHS U01 DK085465NIDDK NIH HHS U01 DK103153
6 · The paper itself

Abstract

objectiveThis study investigated the temporal dynamics of pancreas volume and microstructure in children and adolescents with recent-onset type 1 diabetes (T1D) and individuals without diabetes, including a subset expressing autoantibodies associated with the early stages of T1D. RESEARCH DESIGN AND

methodsMRI was performed in individuals with recent-onset stage 3 T1D (

resultsWithin 100 days of diabetes onset, individuals with T1D had a smaller pancreas (median volume 28.6 mL) than control participants (median volume 48.4 mL;

conclusionsThese results indicate that pancreas volume is decreased in stages 1, 2, and 3 of T1D and decreases during the first year after diabetes onset and that this loss of pancreatic volume is accompanied by microstructural changes.

Indexed as

AdolescentAdultAtrophyAutoantibodiesCase-Control StudiesChildChild, PreschoolCohort StudiesDiabetes Mellitus, Type 1FemaleGlucose Tolerance TestHumansMagnetic Resonance ImagingMaleMiddle AgedOrgan SizeAutoantibodies

Identifiers

PMID30552135
PMCPMC6341292

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.